Intercept Pharmaceuticals Inc  

(Public, NASDAQ:ICPT)   Watch this stock  
Find more results for ICPT
+9.43 (6.70%)
After Hours: 150.13 -0.01 (-0.01%)
Dec 18, 7:59PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 143.75 - 150.50
52 week 54.02 - 497.00
Open 144.83
Vol / Avg. 664,840.00/698,795.00
Mkt cap 3.02B
P/E     -
Div/yield     -
EPS -12.76
Shares 21.36M
Beta     -
Inst. own 60%
Mar 12, 2015
Q4 2014 Intercept Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Dec 2, 2014
Intercept Pharmaceuticals Inc at Deutsche Bank BioFEST
Nov 10, 2014
Intercept Pharmaceuticals Inc to Review its Development Programs (PBC & NASH)
Nov 7, 2014
Q3 2014 Intercept Pharmaceuticals Inc Earnings Release
Nov 7, 2014
Intercept Pharmaceuticals Inc Announces FLINT Trial in NASH Published in The Lancet
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -8047.25% -4180.51%
Operating margin -8098.50% -2432.84%
EBITD margin - -2426.33%
Return on average assets -48.18% -51.65%
Return on average equity -52.18% -91.41%
Employees 50 -
CDP Score - -


SUITE 505, 450 W. 15TH STREET
NEW YORK, NY 10011
United States - Map
+1-646-7471000 (Phone)
+1-646-7471001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.The Company�s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. It is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial, that serves as the basis for seeking regulatory approval in the United States and Europe. As of December 19, 2012, the Company completed enrollment of the POISE trial with 217 patients.

Officers and directors

Jonathan T. Silverstein J.D. Independent Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
Mark Pruzanski M.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Barbara G. Duncan Chief Financial Officer, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
David M. Shapiro M.D. Chief Medical Officer, Executive Vice President - Development
Age: 59
Bio & Compensation  - Reuters
Luciano Adorini M.D. Chief Scientific Officer
Bio & Compensation  - Reuters
Rachel L. McMinn Ph.D. Chief Strategy Officer
Age: 41
Bio & Compensation  - Reuters
Daniel P. Regan Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D., Ph.D. Independent Director
Age: 46
Bio & Compensation  - Reuters
Paolo Fundaro Independent Director
Age: 40
Bio & Compensation  - Reuters
Sanj K. Patel Independent Director
Age: 44
Bio & Compensation  - Reuters